Patents-Review.com
🔗 Permalink
Inventor profile of:

Stuart MILSTEIN

City:

Cambridge, Massachusetts

Country:

United States

Published Applications:

82

Last publication date:

2026-04-09

Top Assignees for applications by Stuart MILSTEIN

The entities that hold a legal rights for patent applications filed by inventor MILSTEIN Stuart:

Recent patent applications by MILSTEIN Stuart

Stuart MILSTEIN from Cambridge, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-09
US20260098263A1
Chemistry; metallurgy

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #2 | 2026-03-12
US20260069625A1
Human necessities

ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES

 #3 | 2025-12-25
US20250388903A1
Chemistry; metallurgy

Methods and Compositions for Adar-Mediated Editing

 #4 | 2025-09-11
US20250283071A1
Chemistry; metallurgy

MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDES

 #5 | 2025-08-28
US20250270555A1
Chemistry; metallurgy

ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES

 #6 | 2025-06-26
US20250205272A1
Human necessities

MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT

 #7 | 2025-01-30
US20250034572A1
Chemistry; metallurgy

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #8 | 2025-01-30
US20250034564A1
Chemistry; metallurgy

Methods and Compositions for ADAR-Mediated Editing

 #9 | 2025-01-30
US20250034563A1
Chemistry; metallurgy

Methods and Compositions for ADAR-Mediated Editing

 #10 | 2024-12-12
US20240409942A1
Chemistry; metallurgy

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #11 | 2024-10-31
US20240358738A1
Human necessities

EXTRAHEPATIC DELIVERY

 #12 | 2024-09-05
US20240294906A1
Chemistry; metallurgy

ATXN2 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING ATXN2-ASSOCIATED NEURODEGENERATIVE DISEASES

 #13 | 2024-08-08
US20240263177A1
Chemistry; metallurgy

Methods and Compositions for Adar-Mediated Editing

 #14 | 2024-01-11
US20240009225A1
Human necessities

Extrahepatic delivery

 #15 | 2023-08-17
US20230256001A1
Human necessities

MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT

 #16 | 2023-06-15
US20230183701A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #17 | 2023-04-27
US20230128522A1
Chemistry; metallurgy

Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

 #18 | 2023-04-13
US20230110876A1
Chemistry; metallurgy

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #19 | 2023-01-19
US20230016929A1
Human necessities

EXTRAHEPATIC DELIVERY

 #20 | 2022-12-08
US20220389424A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #21 | 2022-12-01
US20220380775A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #22 | 2022-11-22
US16461523
Human necessities

Modified RNA agents with reduced off-target effect

 #23 | 2022-09-29
US20220307024A1
Chemistry; metallurgy

DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM

 #24 | 2022-04-28
US20220125823A1
Human necessities

EXTRAHEPATIC DELIVERY

 #25 | 2022-02-24
US20220056448A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #26 | 2022-01-06
US20220002727A1
Chemistry; metallurgy

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #27 | 2022-01-06
US20220002724A1
Chemistry; metallurgy

AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF

 #28 | 2021-10-28
US20210332365A1
Chemistry; metallurgy

Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

 #29 | 2021-01-21
US20210017519A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #30 | 2020-10-29
US20200339991A1
Chemistry; metallurgy

Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof

 #31 | 2020-09-10
US20200283766A1
Chemistry; metallurgy

Compositions and Methods for Inhibiting Expression of Transthyretin

 #32 | 2020-08-20
US20200263176A1
Chemistry; metallurgy

Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes

 #33 | 2020-07-30
US20200239890A1
Chemistry; metallurgy

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #34 | 2020-06-18
US20200190517A1
Chemistry; metallurgy

Organic compositions to treat EPAS1-related diseases

 #35 | 2020-02-20
US20200056175A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR INHIBITIION OF EXPRESSION OF PROTEIN C (PROC) GENES

 #36 | 2019-10-10
US20190309293A1
Chemistry; metallurgy

Compositions and Methods for Inhibiting Expression of Transthyretin

 #37 | 2019-09-12
US20190276827A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #38 | 2019-08-08
US20190241893A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #39 | 2019-08-08
US20190241891A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #40 | 2018-12-20
US20180362978A1
Chemistry; metallurgy

Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes

 #41 | 2018-12-13
US20180355362A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #42 | 2018-10-04
US20180282728A1
Chemistry; metallurgy

ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES

 #43 | 2018-06-07
US20180153919A1
Human necessities

ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES

 #44 | 2018-04-12
US20180100151A1
Chemistry; metallurgy

Organic compositions to treat EPAS1-related diseases

 #45 | 2018-03-08
US20180066255A1
Chemistry; metallurgy

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #46 | 2017-11-16
US20170327829A1
Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

 #47 | 2017-11-09
US20170321213A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of transthyretin

 #48 | 2017-09-28
US20170275626A1
Chemistry; metallurgy

Modified double-stranded RNA agents

 #49 | 2017-03-16
US20170073678A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #50 | 2017-01-05
US20170000815A1
Human necessities

LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE

 #51 | 2016-11-17
US20160333342A1
Chemistry; metallurgy

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

 #52 | 2016-09-22
US20160272979A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #53 | 2016-09-15
US20160264963A1
Chemistry; metallurgy

Compositions and Methods for Inhibiting Expression of Transthyretin

 #54 | 2016-06-30
US20160186172A1
Chemistry; metallurgy

Compositions and methods for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

 #55 | 2016-01-28
US20160024499A1
Chemistry; metallurgy

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #56 | 2016-01-14
US20160010089A1
Chemistry; metallurgy

Organic compositions to treat EPAS1-related diseases

 #57 | 2015-10-15
US20150291954A1
Chemistry; metallurgy

Organic compositions to treat beta-catenin-related diseases

 #58 | 2015-10-08
US20150284721A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #59 | 2015-10-01
US20150275218A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #60 | 2015-08-27
US20150238515A1
Human necessities

ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES

 #61 | 2014-07-10
US20140194493A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of transthyretin

 #62 | 2014-06-26
US20140179768A1
Chemistry; metallurgy

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

 #63 | 2014-05-22
US20140142162A1
Chemistry; metallurgy

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #64 | 2014-05-08
US20140127325A1
Chemistry; metallurgy

Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

 #65 | 2014-05-01
US20140121263A1
Chemistry; metallurgy

LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE

 #66 | 2014-04-24
US20140113957A1
Chemistry; metallurgy

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

 #67 | 2014-04-17
US20140107179A1
Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

 #68 | 2014-02-06
US20140039039A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #69 | 2014-01-16
US20140018410A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of klf-1 and bcl11a genes

 #70 | 2013-11-28
US20130317081A1
Chemistry; metallurgy

Serpinc1 iRNA compositions and methods of use thereof

 #71 | 2013-02-07
US20130035371A1
Human necessities

Lipid formulated dsRNA targeting the PCSK9 gene

 #72 | 2013-01-10
US20130012571A1
Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

 #73 | 2012-09-06
US20120225927A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of transthyretin

 #74 | 2012-05-24
US20120129915A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #75 | 2012-05-24
US20120129914A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #76 | 2012-05-17
US20120122960A1
Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

 #77 | 2012-05-10
US20120115934A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #78 | 2012-05-10
US20120115933A1
Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

 #79 | 2011-10-27
US20110263681A1
Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

 #80 | 2011-07-07
US20110166058A1
Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

 #81 | 2011-01-20
US20110015252A1
Human necessities

Lipid formulated dsRNA targeting the PCSK9 gene

 #82 | 2010-05-13
US20100120893A1
Chemistry; metallurgy

Compositions and methods for inhibiting expression of transthyretin
InventorID:

30204 ⎘